Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Treatment
Share your love
EyeBio Raises $130M for Restoret Development
EyeBio announced the successful completion of an extension to its Series A financing, resulting in a total raised amount of $130 million to date. The funding will be utilized by EyeBio to accelerate the company’s clinical development program and expand…
FDA Warns Amazon Over Sale of 7 Unapproved Eye Drops
The US Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER) has issued a warning letter to e-commerce giant Amazon.com regarding the introduction of unapproved ophthalmic drug products into interstate commerce. The FDA’s warning, delivered in a…
CHMP Backs Bayer’s High-Dose Eylea for Retinal Diseases
Bayer announced on Friday that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of a high-dose formulation of the renowned eye drug Eylea for the treatment of wet age-related macular degeneration and…
VSY Biotechnology to Introduce a Novel Anti-VEGF for AMD
VSY Biotechnology GmbH is proud to announce the groundbreaking development of Varliciment, a revolutionary anti-VEGF agent for the treatment of age-related macular degeneration (AMD). Varliciment distinguishes itself from existing anti-VEGF agents like brolucizumab, namely Novartis’ Beovu, by being non-generic. This…
World’s First Whole-Eye and Face Transplant Breakthrough
In a groundbreaking medical feat, a surgical team comprising more than 140 clinicians, including surgeons, nurses, and various healthcare professionals from New York University (NYU) Langone Health, has successfully conducted the world’s first whole-eye and partial face transplantation on a…
AMD Forecast: New Algorithm Offers 94% Accuracy
Researchers at Duke University have developed a computer program that can predict with 94% accuracy whether an individual’s age-related macular degeneration (AMD) will deteriorate within a year. The deep learning algorithm, featured in an article within JAMA Ophthalmology, evaluates comprehensive…
Ocular Therapeutix Gets FDA Agreement for Wet AMD Trial
Ocular Therapeutix has obtained written FDA approval for the comprehensive design of its pivotal phase 3 clinical trial, known as the SOL trial, which evaluates Axpaxli (axitinib intravitreal implant) for treating wet age-related macular degeneration (AMD) under a Special Protocol…
What Is Idiopathic Multifocal Choroiditis and How to Manage It|OBN
What Is Idiopathic Multifocal Choroiditis? Idiopathic Multifocal Choroiditis (IMFC) is a rare eye condition that primarily affects the choroid, a vascular layer situated between the retina and the sclera (the white part of the eye). The condition is characterized by…
Bausch + Lomb Acquires Eye Drugs from Novartis
Bausch + Lomb has announced that it will acquire the dry eye drug Xiidra (lifitegrast ophthalmic solution) 5% from Novartis. Xiidra is an eye drop without steroids that has received specific approval for treating the signs and symptoms of dry…
What Is Leber Congenital Amaurosis?
Leber Congenital Amaurosis (LCA) is a rare genetic disorder that affects the retina, the part of the eye responsible for sensing light and sending visual signals to the brain. It is a severe form of retinal dystrophy, which means that…